Table 2.

Importance of Different Populations when Considering Amyloid PET Use

Survey question: How important would it be to test for Alzheimer disease in:	Clinicians (n=103)	Patients Stakeholders (n=102)	P-value
1: All individuals over 65 years-old, regardless of whether or not they complain of memory problems?	2 (IQR 1–5) Range 1–9	7 (IQR 6–9) Range 1–9	<0.001
2: People at increased risk for Alzheimer disease (e.g. due to family history) who do not complain of any memory or thinking problems?	4 (IQR 2–7) Range 1–9	8 (IQR 7–9) Range 2–9	<0.001
3: People who complain of trouble with memory and thinking but who do not have any problems found on memory testing?	5 (IQR 3–7) Range 1–9	8 (IQR 7–9) Range 2–9	<0.001
4: People with mild difficulties in memory (mild cognitive impairment), which puts them at a higher risk of developing dementia (more severe problems with memory and thinking)?	7 (IQR 6–8) Range 1–9	8 (IQR 7–9)* Range 4–9	0.003
5. People with trouble with memory and thinking impacting activities in daily life (dementia) that fits a typical Alzheimer disease dementia pattern?	7 (IQR 5–8) Range 1–9	8 (IQR 7–9) Range 4–9	<0.001
6: People with trouble with memory and thinking impacting activities in daily life (dementia) that does not fit a typical dementia pattern, where doctors are having difficulty giving a clear diagnosis?	8 (IQR 7–9) Range 1–9	8 (IQR 7–9) Range 1–9	0.937

Responses: Limited importance 1–3, important 4–6, critical importance 7–9. Data presented as median (interquartile range, IQR).

^*n=101 for this question